Oncolytic Virus Immunotherapy Market Will Generate New Growth Opportunities by 2017 – 2025

In 2015, the first Oncolytic virus immunotherapy was approved, and Oncolytic Immunotherapy represents a new and an exciting area of cancer therapy. Oncology Immunotherapy exploits virus's ability to replicate selectively and kill tumor tissue while at the same time regulate the specific immune response of a patient The first oncolytic virus to demonstrate a clinical benefit in patients with melanoma is genetically modified herpes simplex virus type I i.e. Talimogene laherparepvec (T-VEC).

Nearly 48 oncolytic virus therapy are in clinical trial. The purpose of developing a new therapy for the treatment of cancer is because of the side-effects caused by conventional chemotherapy and radiotherapy. Imlygic is an advanced therapy medicine used to treat adults with melanoma which cannot be treated surgically and has spread to the other parts of the body but no to lung, brain or bone. It is available as a solution in two different strength and the volume to be injected depends on the number and size of the tumors to be injected. The most common serious side effects of oncolytic virus immunotherapy are cellutus.

Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/15262

Oncolytic Virus Immunotherapy Market: Drivers and Restraints

The past decades have shown the higher prevalence and incidence for melanoma, and globally, the scenario is worsening with the increase in a number of patients with cancer. Development of new therapy i.e. oncolytic virus immunotherapy for melanoma is to have higher potency towards the malignant cells with no or low toxic effect as compared to other conventional and chemotherapy. These are the possible drivers for the growth of oncolytic virus immunotherapy market. Other drivers such as an increase in global warming affecting the skin, aggressive marketing strategies along with huge investment in research and development for the development of treatment methods had led to significant increase in oncolytic virus immunotherapy. challenges are faced by researchers in developing oncolytic virus as a new class of anti-cancer immunotherapy, so it requires more practical clinical trials design and assessment criterion, as well as the costly nature of cell lines and irreplaceable samples, are restraining the oncolytic virus immunotherapy market.

Oncolytic Virus Immunotherapy Market: Overview

. There are seven main categories in which Current immunotherapy approaches for melanoma fall: oncolytic virus therapies checkpoint inhibitors, cancer vaccines, adjuvant immunotherapy monoclonal antibodies, adoptive cell therapy, and cytokines. To increase the effectiveness of oncolytic virus therapy and broaden its applicability is an aim of the ongoing research. A phase I clinical trial of Cavatak™, Toca 51 and GL-ONC1 are oncolytic virus immunotherapy drug for melanoma.

View Sample Report @ http://www.persistencemarketresearch.com/samples/15262

Oncolytic Virus Immunotherapy Market: Region-wise Outlook

North America is leading in the oncolytic virus immunotherapy market globally, according to Skin Cancer Foundation Statistics, Globally 132,000 melanoma skin cancers occur each year. One in every three cancers diagnosed is a skin cancer, and one in every five Americans will develop skin cancer in their lifetime. North America has well-developed healthcare infrastructure with massive investment in research and development of oncolytic virus immunotherapy.

Oncolytic Virus Immunotherapy Market: Key Market Participants

Imlygic, an oncolytic virus immunotherapy drug, is marketed by Amgen Inc., but however several other competitors are expected to enter in oncolytic virus immunotherapy in the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also includes projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

To view complete report @ http://www.persistencemarketresearch.com/market-research/oncolytic-virus-immunotherapy-market.asp

About Us 
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
 PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
 

Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:www.persistencemarketresearch.com

This release was published on openPR.